Giancarlo Vecchio

Giancarlo Vecchio


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2002
Verified
Journal Article
Closed access
FCFrancesca Carlomagno
Francesca Carlomagno
DVDonata Vitagliano
Donata Vitagliano
TGTeresa Guida
Teresa Guida
Fortunato CiardielloFortunato Ciardiello
Fortunato Ciardiello
Giampaolo TortoraGiampaolo Tortora
Giampaolo Tortora
MSMassimo Santoro
Massimo Santoro

1 June 2002 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MSMassimo Santoro
Massimo Santoro
Rosa Marina MelilloRosa Marina Melillo
Rosa Marina Melillo
FCFrancesca Carlomagno
Francesca Carlomagno
Alfredo FuscoAlfredo Fusco
Alfredo Fusco
GVGiancarlo Vecchio
Giancarlo Vecchio

7 June 2019 in Cancers
Verified
Journal Article
Open access
PDF file
FCFrancesca Collina
Francesca Collina
LSLucia La Sala
Lucia La Sala
FLFederica Liotti
Federica Liotti
NPNella Prevete
Nella Prevete
EMElvira La Mantia
Elvira La Mantia
RFRenato Franco
Renato Franco
Papillary thyroid carcinomas (PTCs) have an excellent prognosis, but a fraction of them show aggressive behavior, becoming radioiodine (RAI)-resistant and/or metastatic. AXL (Anexelekto) is a tyrosine kinase receptor regulating viability, invasiveness and chemoresistance in various human cancers, including PTCs. Here, we analyze the role of AXL in PTC prognosis and as a marker of RAI refractoriness. Immunohistochemistry was used to assess AXL positivity in a cohort of human PTC samples. Normal and cancerous thyroid cell lines were used in vitro for signaling, survival and RAI uptake evaluations. 38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation. In human PTC samples, AXL expression correlated with V-akt murine thymoma viral oncogene homolog 1 (AKT1) and p65 nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activation levels. Consistently, AXL stimulation with its ligand growth arrest-specific gene 6 (GAS6) increased AKT1- and p65 NF-kB-phosphorylation and promoted survival of thyroid cancer cell lines in culture. Enforced expression or activation of AXL in normal rat thyroid cells significantly reduced the expression of the sodium/iodide symporter (NIS) and the radioiodine uptake. These data indicate that AXL expression levels could be used as predictor of RAI refractoriness and as a possible novel therapeutic target of RAI resistant PTCs.

1 June 1998 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
MSMassimo Mattia SANTORO
Massimo Mattia SANTORO
Rosa Marina MelilloRosa Marina Melillo
Rosa Marina Melillo
FCF Carlomagno
F Carlomagno
Roberta ViscontiRoberta Visconti
Roberta Visconti
GVGabriella De Vita
Gabriella De Vita
GVGiancarlo Vecchio
Giancarlo Vecchio

15 February 2002
Verified
Journal Article
Closed access
FCFrancesca Carlomagno
Francesca Carlomagno
DVDonata Vitagliano
Donata Vitagliano
TGTeresa Guida
Teresa Guida
MNMaria Napolitano
Maria Napolitano
GVGiancarlo Vecchio
Giancarlo Vecchio
MSMassimo Santoro
Massimo Santoro

1 October 2000 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
Domenico SalvatoreDomenico Salvatore
Domenico Salvatore
Maria Vittoria BaroneMaria Vittoria Barone
Maria Vittoria Barone
Giuliana SalvatoreGiuliana Salvatore
Giuliana Salvatore
Rosa Marina MelilloRosa Marina Melillo
Rosa Marina Melillo
GCGennaro Chiappetta
Gennaro Chiappetta
MSMassimo Santoro
Massimo Santoro
Point mutations of the RET receptor tyrosine kinase are responsible for the inheritance of multiple endocrine neoplasia (MEN) type 2 syndromes and are also present in a fraction of sporadic medullary thyroid carcinomas. Somatic rearrangements of the RET gene generating the chimeric RET/papillary thyroid carcinoma (PTC) oncogenes are the predominant molecular lesions associated with papillary carcinoma, the most frequent thyroid malignancy in humans. Oncogenic mutations cause constitutive activation of the kinase function of RET, which, in turn, results in the autophosphorylation of RET tyrosine residues critical for signaling. In vitro kinase assays previously revealed six putative RET autophosphorylation sites. The aim of the present study was to assess the phosphorylation of two such residues, tyrosines 1015 and 1062 (Y1015 and Y1062), in the in vivo signaling of RET and RET-derived oncogenes. Using phosphorylated RET-specific antibodies, we demonstrate that both Y1015 and Y1062 are rapidly phosphorylated upon ligand triggering of RET. Moreover, regardless of the nature of the underlying activating mutation, the concomitant phosphorylation of Y1015 and Y1062 is a common feature of the various oncogenic RET products (MEN2A, MEN2B, and PTC). This study shows that Ab-pY1062 is a useful tool with which to detect activated RET in human tumor cells and surgical samples. Finally, the microinjection of Ab-pY1062 antibodies into living cells demonstrates that Ret/PTC1 signaling is required to maintain the mitogenesis of a human carcinoma cell line expressing the Ret/PTC1 oncoprotein.